Information regarding a specific phone number for Zilbrysq is not publicly available in the provided context.
Who Makes Zilbrysq?
Zilbrysq is manufactured by Viatris [1].
What is Zilbrysq Used For?
Zilbrysq is indicated for the treatment of allogeneic stem cell transplant (ASCT)-ineligible adults with relapsed or refractory follicular lymphoma (FL) who have had at least two prior lines of systemic therapy [1].
How Does Zilbrysq Work?
Zilbrysq is a kinase inhibitor. It is a small molecule that targets Bruton's tyrosine kinase (BTK) [1].
When Can Zilbrysq Be Prescribed?
Zilbrysq can be prescribed for adult patients with relapsed or refractory follicular lymphoma (FL) who have already undergone at least two prior systemic treatments and are not eligible for an allogeneic stem cell transplant [1].
What Are the Side Effects of Zilbrysq?
Common side effects associated with Zilbrysq include neutropenia, thrombocytopenia, anemia, and diarrhea [1].
Are There Alternatives to Zilbrysq?
For patients with relapsed or refractory follicular lymphoma, other treatment options may include chemotherapy, immunotherapy, or other targeted therapies, depending on individual patient factors and prior treatments [1].
What is the Patent Status of Zilbrysq?
Information about the specific patent status and expiry dates for Zilbrysq is not detailed in the provided materials. For comprehensive details on drug patents, including those for Zilbrysq, resources like DrugPatentWatch.com are available [2].
What are the Risks Associated with Zilbrysq Treatment?
Zilbrysq treatment carries risks of serious side effects, including infections, bleeding, and cardiovascular events. Patients should be monitored closely by their healthcare provider [1].
How is Zilbrysq Administered?
Zilbrysq is administered orally [1].
What Clinical Data Supports Zilbrysq's Efficacy?
The efficacy of Zilbrysq was evaluated in a clinical trial that demonstrated a significant improvement in progression-free survival for patients treated with Zilbrysq compared to placebo [1].
Sources:
[1] https://www.viatrismedia.com/2024/06/18/viatrismeds- Zilbrysq-taporfinib-receives-us-fda-approval-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma-in-adults/
[2] https://drugpatentwatch.com/